# Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

> **NCT02589522** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 15 (actual)

## Conditions studied

- Metastatic Lung Neuroendocrine Neoplasm
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Lung Small Cell Carcinoma
- Metastatic Malignant Neoplasm in the Brain
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **DRUG:** Berzosertib
- **OTHER:** Quality-of-Life Assessment
- **PROCEDURE:** Therapeutic Conventional Surgery
- **RADIATION:** Whole-Brain Radiotherapy

## Key facts

- **NCT ID:** NCT02589522
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-05-22
- **Primary completion:** 2021-08-23
- **Final completion:** 2026-09-18
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02589522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02589522, "Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02589522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*